nivolumab,Regorafenib,botensilimab,balstilimab
bms,bayer,agenus
 with what was seen in subgroups in regonivo and now the 0% response rate in liver met+ vs 42% in liver met-, pts, its becoming clearer by the day. these are interesting. 
Patient Advocate. Knowledge Dispersion. #ClinicalTrials LifeTrials - Coming Soon.
Dont let the perfect become the enemy of the good